James Mock - Moderna Chief Officer
| M1RN34 Stock | BRL 9.48 0.02 0.21% |
Insider
James Mock is Chief Officer of Moderna
| Age | 46 |
| Phone | 617 714 6500 |
| Web | https://www.modernatx.com |
James Mock Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Mock against Moderna stock is an integral part of due diligence when investing in Moderna. James Mock insider activity provides valuable insight into whether Moderna is net buyers or sellers over its current business cycle. Note, Moderna insiders must abide by specific rules, including filing SEC forms every time they buy or sell Moderna'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Mock over two months ago Disposition of 1453 shares by James Mock of Moderna subject to Rule 16b-3 | ||
James Mock over six months ago Disposition of 705 shares by James Mock of Moderna at 101.9281 subject to Rule 16b-3 |
Moderna Management Efficiency
The company has return on total asset (ROA) of 0.3526 % which means that it generated a profit of $0.3526 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.8369 %, meaning that it generated $0.8369 on every $100 dollars invested by stockholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brent Hyder | salesforce inc | 58 | |
| Sarah Franklin | salesforce inc | N/A | |
| Kanetsugu Mike | Mitsubishi UFJ Financial | 67 | |
| James DeMare | Bank of America | 53 | |
| Atsushi Miyata | Mitsubishi UFJ Financial | 59 | |
| Hideaki Takase | Mitsubishi UFJ Financial | 55 | |
| Rudolf Bless | Bank of America | N/A | |
| Tetsuya Yonehana | Mitsubishi UFJ Financial | 59 | |
| Hironori Kamezawa | Mitsubishi UFJ Financial | 62 | |
| Aditya Bhasin | Bank of America | 49 | |
| David Schmaier | salesforce inc | N/A | |
| Matthew Koder | Bank of America | 51 | |
| Darrin Boland | Bank of America | 54 | |
| Yoshitaka Shiba | Mitsubishi UFJ Financial | 62 | |
| Thomas Scrivener | Bank of America | 51 | |
| Taka Saka | Mitsubishi UFJ Financial | N/A | |
| Alastair Borthwick | Bank of America | 54 | |
| Toshiki Ochi | Mitsubishi UFJ Financial | 55 | |
| Brian Millham | salesforce inc | 54 | |
| Christopher Hyzy | Bank of America | N/A | |
| Srinivas Tallapragada | salesforce inc | 53 | |
Management Performance
| Return On Equity | 0.84 | |||
| Return On Asset | 0.35 |
Moderna Leadership Team
Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shannon Klinger, Chief Sec | ||
| James Mock, Chief Officer | ||
| Stephane Bancel, CEO Director | ||
| John Reynders, Chief Officer | ||
| Jerh Collins, Chief Officer | ||
| Lavina CFA, VP Relations | ||
| Juan Andres, Pres Expansion | ||
| Melissa Moore, Chief Board | ||
| Noubar Afeyan, Independent CoFounder | ||
| Stephen MD, President |
Moderna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.84 | |||
| Return On Asset | 0.35 | |||
| Profit Margin | 0.55 % | |||
| Operating Margin | 0.62 % | |||
| Current Valuation | 387.59 B | |||
| Shares Outstanding | 7.68 B | |||
| Price To Book | 4.44 X | |||
| Price To Sales | 19.80 X | |||
| Revenue | 18.47 B | |||
| Gross Profit | 13.86 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Moderna Stock
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.